{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:44:37Z","timestamp":1790138677992,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:00:00Z","timestamp":1499644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1038\/leu.2017.216","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T06:41:09Z","timestamp":1499668869000},"page":"323-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20\/RNF40\/WAC-H2B ubiquitination axis"],"prefix":"10.1038","volume":"32","author":[{"given":"P","family":"Garrido Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E H J","family":"van Roon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S S","family":"Pinhan\u00e7os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kerstjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"te Kronnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R W","family":"Stam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"key":"BFleu2017216_CR1","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/leu.2013.135","volume":"27","author":"C Meyer","year":"2013","unstructured":"Meyer C, Hofmann J, Burmeister T, Groger D, Park TS, Emerenciano M et al. The MLL recombinome of acute leukemias in 2013. Leukemia 2013; 27: 2165\u20132176.","journal-title":"Leukemia"},{"key":"BFleu2017216_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/sj.leu.2404578","volume":"21","author":"MW Jansen","year":"2007","unstructured":"Jansen MW, Corral L, van der Velden VH, Panzer-Grumayer R, Schrappe M, Schrauder A et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia 2007; 21: 633\u2013641.","journal-title":"Leukemia"},{"key":"BFleu2017216_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ng765","volume":"30","author":"SA Armstrong","year":"2002","unstructured":"Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41\u201347.","journal-title":"Nat Genet"},{"key":"BFleu2017216_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1535-6108(02)00032-6","volume":"1","author":"EJ Yeoh","year":"2002","unstructured":"Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133\u2013143.","journal-title":"Cancer Cell"},{"key":"BFleu2017216_CR5","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1182\/blood-2009-07-233049","volume":"115","author":"RW Stam","year":"2010","unstructured":"Stam RW, Schneider P, Hagelstein JA, van der Linden MH, Stumpel DJ, de Menezes RX et al. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood 2010; 115: 2835\u20132844.","journal-title":"Blood"},{"key":"BFleu2017216_CR6","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1182\/blood-2009-06-227660","volume":"114","author":"DJ Stumpel","year":"2009","unstructured":"Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 2009; 114: 5490\u20135498.","journal-title":"Blood"},{"key":"BFleu2017216_CR7","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1182\/blood-2009-09-243634","volume":"115","author":"E Schafer","year":"2010","unstructured":"Schafer E, Irizarry R, Negi S, McIntyre E, Small D, Figueroa ME et al. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood 2010; 115: 4798\u20134809.","journal-title":"Blood"},{"key":"BFleu2017216_CR8","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1101\/gad.1741408","volume":"22","author":"MG Guenther","year":"2008","unstructured":"Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev 2008; 22: 3403\u20133408.","journal-title":"Genes Dev"},{"key":"BFleu2017216_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccr.2008.10.001","volume":"14","author":"AV Krivtsov","year":"2008","unstructured":"Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008; 14: 355\u2013368.","journal-title":"Cancer Cell"},{"key":"BFleu2017216_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ccr.2009.12.040","volume":"17","author":"A Yokoyama","year":"2010","unstructured":"Yokoyama A, Lin M, Naresh A, Kitabayashi I, Cleary ML . A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 2010; 17: 198\u2013212.","journal-title":"Cancer Cell"},{"key":"BFleu2017216_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.molcel.2010.01.026","volume":"37","author":"C Lin","year":"2010","unstructured":"Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L et al. AFF4, a component of the ELL\/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010; 37: 429\u2013437.","journal-title":"Mol Cell"},{"key":"BFleu2017216_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/hmg\/ddl444","volume":"16","author":"E Bitoun","year":"2007","unstructured":"Bitoun E, Oliver PL, Davies KE . The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 2007; 16: 92\u2013106.","journal-title":"Hum Mol Genet"},{"key":"BFleu2017216_CR13","doi-asserted-by":"publisher","first-page":"E636","DOI":"10.1073\/pnas.1107107108","volume":"108","author":"N He","year":"2011","unstructured":"He N, Chan CK, Sobhian B, Chou S, Xue Y, Liu M et al. Human polymerase-associated factor complex (PAFc) connects the super elongation complex (SEC) to RNA polymerase II on chromatin. Proc Natl Acad Sci USA 2011; 108: E636\u2013E645.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2017216_CR14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ccr.2010.04.012","volume":"17","author":"AG Muntean","year":"2010","unstructured":"Muntean AG, Tan J, Sitwala K, Huang Y, Bronstein J, Connelly JA et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 2010; 17: 609\u2013621.","journal-title":"Cancer Cell"},{"key":"BFleu2017216_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10509","volume":"478","author":"MA Dawson","year":"2011","unstructured":"Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011; 478: 529\u2013533.","journal-title":"Nature"},{"key":"BFleu2017216_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/hmg\/ddr490","volume":"21","author":"MA Hahn","year":"2012","unstructured":"Hahn MA, Dickson KA, Jackson S, Clarkson A, Gill AJ, Marsh DJ . The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of histone 2B monoubiquitination. Hum Mol Genet 2012; 21: 559\u2013568.","journal-title":"Hum Mol Genet"},{"key":"BFleu2017216_CR17","doi-asserted-by":"publisher","first-page":"e1000249","DOI":"10.1371\/journal.pbio.1000249","volume":"7","author":"D Mueller","year":"2009","unstructured":"Mueller D, Garcia-Cuellar MP, Bach C, Buhl S, Maethner E, Slany RK . Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol 2009; 7: e1000249.","journal-title":"PLoS Biol"},{"key":"BFleu2017216_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","volume":"20","author":"KM Bernt","year":"2011","unstructured":"Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011; 20: 66\u201378.","journal-title":"Cancer Cell"},{"key":"BFleu2017216_CR19","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1073\/pnas.1301045110","volume":"110","author":"E Wang","year":"2013","unstructured":"Wang E, Kawaoka S, Yu M, Shi J, Ni T, Yang W et al. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia. Proc Natl Acad Sci USA 2013; 110: 3901\u20133906.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2017216_CR20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/leu.2011.278","volume":"26","author":"DJ Stumpel","year":"2012","unstructured":"Stumpel DJ, Schneider P, Seslija L, Osaki H, Williams O, Pieters R et al. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia 2012; 26: 682\u2013692.","journal-title":"Leukemia"},{"key":"BFleu2017216_CR21","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/leu.2010.155","volume":"24","author":"A Gessner","year":"2010","unstructured":"Gessner A, Thomas M, Castro PG, Buchler L, Scholz A, Brummendorf TH et al. Leukemic fusion genes MLL\/AF4 and AML1\/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. Leukemia 2010; 24: 1751\u20131759.","journal-title":"Leukemia"},{"key":"BFleu2017216_CR22","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.3324\/haematol.2014.122119","volume":"101","author":"MH van der Linden","year":"2016","unstructured":"van der Linden MH, Boer JM, Schneider P, Willekes M, Seslija L, De Lorenzo P et al. Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities. Haematologica 2016; 101: e95\u2013e98.","journal-title":"Haematologica"},{"key":"BFleu2017216_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.mce.2011.11.025","volume":"350","author":"T Jaaskelainen","year":"2012","unstructured":"Jaaskelainen T, Makkonen H, Visakorpi T, Kim J, Roeder RG, Palvimo JJ . Histone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth. Mol Cell Endocrinol 2012; 350: 87\u201398.","journal-title":"Mol Cell Endocrinol"},{"key":"BFleu2017216_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.molcel.2011.01.024","volume":"41","author":"F Zhang","year":"2011","unstructured":"Zhang F, Yu X . WAC, a functional partner of RNF20\/40, regulates histone H2B ubiquitination and gene transcription. Mol Cell 2011; 41: 384\u2013397.","journal-title":"Mol Cell"},{"key":"BFleu2017216_CR25","first-page":"269","volume":"6","author":"H Bailey","year":"2015","unstructured":"Bailey H, Stenehjem DD, Sharma S . Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med 2015; 6: 269\u2013276.","journal-title":"J Blood Med"},{"key":"BFleu2017216_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11060-011-0717-z","volume":"107","author":"J Drappatz","year":"2012","unstructured":"Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R et al. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol 2012; 107: 133\u2013138.","journal-title":"J Neurooncol"},{"key":"BFleu2017216_CR27","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014; 15: 1195\u20131206.","journal-title":"Lancet Oncol"},{"key":"BFleu2017216_CR28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.cell.2007.09.046","volume":"131","author":"JS Lee","year":"2007","unstructured":"Lee JS, Shukla A, Schneider J, Swanson SK, Washburn MP, Florens L et al. Histone crosstalk between H2B monoubiquitination and H3 methylation mediated by COMPASS. Cell 2007; 131: 1084\u20131096.","journal-title":"Cell"},{"key":"BFleu2017216_CR29","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1021\/cb9002255","volume":"4","author":"RK McGinty","year":"2009","unstructured":"McGinty RK, Kohn M, Chatterjee C, Chiang KP, Pratt MR, Muir TW . Structure-activity analysis of semisynthetic nucleosomes: mechanistic insights into the stimulation of Dot1L by ubiquitylated histone H2B. ACS Chem Biol 2009; 4: 958\u2013968.","journal-title":"ACS Chem Biol"},{"key":"BFleu2017216_CR30","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cell.2009.02.027","volume":"137","author":"J Kim","year":"2009","unstructured":"Kim J, Guermah M, McGinty RK, Lee JS, Tang Z, Milne TA et al. RAD6-Mediated transcription-coupled H2B ubiquitylation directly stimulates H3K4 methylation in human cells. Cell 2009; 137: 459\u2013471.","journal-title":"Cell"},{"key":"BFleu2017216_CR31","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.1128\/MCB.21.17.5979-5991.2001","volume":"21","author":"YL Yao","year":"2001","unstructured":"Yao YL, Yang WM, Seto E . Regulation of transcription factor YY1 by acetylation and deacetylation. Mol Cell Biol 2001; 21: 5979\u20135991.","journal-title":"Mol Cell Biol"},{"key":"BFleu2017216_CR32","doi-asserted-by":"publisher","first-page":"11482","DOI":"10.3390\/ijms160511482","volume":"16","author":"H Nural-Guvener","year":"2015","unstructured":"Nural-Guvener H, Zakharova L, Feehery L, Sljukic S, Gaballa M . Anti-fibrotic effects of class I HDAC inhibitor, mocetinostat is associated with IL-6\/Stat3 signaling in ischemic heart failure. Int J Mol Sci 2015; 16: 11482\u201311499.","journal-title":"Int J Mol Sci"},{"key":"BFleu2017216_CR33","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/leu.2011.340","volume":"26","author":"M Gupta","year":"2012","unstructured":"Gupta M, Han JJ, Stenson M, Wellik L, Witzig TE . Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 2012; 26: 1356\u20131364.","journal-title":"Leukemia"},{"key":"BFleu2017216_CR34","doi-asserted-by":"publisher","first-page":"30358","DOI":"10.1074\/jbc.M401359200","volume":"279","author":"L Klampfer","year":"2004","unstructured":"Klampfer L, Huang J, Swaby LA, Augenlicht L . Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem 2004; 279: 30358\u201330368.","journal-title":"J Biol Chem"},{"key":"BFleu2017216_CR35","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood-2008-01-133769","volume":"112","author":"D Buglio","year":"2008","unstructured":"Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008; 112: 1424\u20131433.","journal-title":"Blood"},{"key":"BFleu2017216_CR36","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","volume":"18","author":"JJ Kovacs","year":"2005","unstructured":"Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005; 18: 601\u2013607.","journal-title":"Mol Cell"},{"key":"BFleu2017216_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.dnarep.2011.10.014","volume":"11","author":"H Wang","year":"2012","unstructured":"Wang H, Zhou W, Zheng Z, Zhang P, Tu B, He Q et al. The HDAC inhibitor depsipeptide transactivates the p53\/p21 pathway by inducing DNA damage. DNA Repair (Amst) 2012; 11: 146\u2013156.","journal-title":"DNA Repair (Amst)"},{"key":"BFleu2017216_CR38","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/sj.bjp.0707608","volume":"153","author":"F Condorelli","year":"2008","unstructured":"Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL . Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008; 153: 657\u2013668.","journal-title":"Br J Pharmacol"},{"issue":"Pt 8","key":"BFleu2017216_CR39","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1242\/jcs.03431","volume":"120","author":"AD Tran","year":"2007","unstructured":"Tran AD, Marmo TP, Salam AA, Che S, Finkelstein E, Kabarriti R et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 2007; 120 (Pt 8): 1469\u20131479.","journal-title":"J Cell Sci"},{"key":"BFleu2017216_CR40","doi-asserted-by":"publisher","first-page":"D512","DOI":"10.1093\/nar\/gku1267","volume":"43","author":"PV Hornbeck","year":"2015","unstructured":"Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E . PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res 2015; 43: D512\u2013D520.","journal-title":"Nucleic Acids Res"},{"key":"BFleu2017216_CR41","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.celrep.2015.10.013","volume":"13","author":"CB Greer","year":"2015","unstructured":"Greer CB, Tanaka Y, Kim YJ, Xie P, Zhang MQ, Park IH et al. Histone deacetylases positively regulate transcription through the elongation machinery. Cell Rep 2015; 13: 1444\u20131455.","journal-title":"Cell Rep"},{"key":"BFleu2017216_CR42","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/embor.2009.108","volume":"10","author":"J Pirngruber","year":"2009","unstructured":"Pirngruber J, Shchebet A, Schreiber L, Shema E, Minsky N, Chapman RD et al. CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3'-end processing. EMBO Rep 2009; 10: 894\u2013900.","journal-title":"EMBO Rep"},{"key":"BFleu2017216_CR43","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cell.2006.04.029","volume":"125","author":"R Pavri","year":"2006","unstructured":"Pavri R, Zhu B, Li G, Trojer P, Mandal S, Shilatifard A et al. Histone H2B monoubiquitination functions cooperatively with FACT to regulate elongation by RNA polymerase II. Cell 2006; 125: 703\u2013717.","journal-title":"Cell"},{"key":"BFleu2017216_CR44","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature14888","volume":"525","author":"CY Fong","year":"2015","unstructured":"Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 2015; 525: 538\u2013542.","journal-title":"Nature"},{"key":"BFleu2017216_CR45","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature14898","volume":"525","author":"P Rathert","year":"2015","unstructured":"Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 2015; 525: 543\u2013547.","journal-title":"Nature"},{"key":"BFleu2017216_CR46","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/leu.2012.31","volume":"26","author":"A Vilas-Zornoza","year":"2012","unstructured":"Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A et al. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia 2012; 26: 1517\u20131526.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017216","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:08:33Z","timestamp":1684433313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,10]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["BFleu2017216"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.216","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,10]]},"assertion":[{"value":"10 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}